(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return — typically within a year following completion of their initial treatment. Today, the current standard of care following initial chemotherapy is to "watch and wait," an approach that monitors the patient for signs of relapse.

But what if there were a way to identify patients at risk of relapse earlier and treat them before the cancer has a chance to come back? That's the goal of the ALPHA3 clinical trial, a groundbreaking study investigating whether early intervention with an investigational CAR T cell product (cemacabtagene ansegedleucel or cem

See Full Page